Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder

Brain, Behavior, and Immunity

Volumn 25, Issue 6, 2011, Pages 1272-1278

  Sublette, M Elizabeth ^a,b   Galfalvy, Hanga C ^a,b   Fuchs, Dietmar ^c   Lapidus, Manana ^b   Grunebaum, Michael F ^a,b   Oquendo, Maria A ^a,b   John Mann, J ^a,b   Postolache, Teodor T ^d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Depression; Inflammation; Kynurenine; Major depressive disorder; Neopterin; Serotonin; Suicide; Tryptophan

Indexed keywords

CYTOKINE; KYNURENINE; NEOPTERIN; TRYPTOPHAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CYTOKINE PRODUCTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SUICIDE ATTEMPT; VOLUNTEER;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYPERICUM; IMPULSIVE BEHAVIOR; INFLAMMATION; KYNURENINE; MALE; MIDDLE AGED; NEOPTERIN; PHYTOTHERAPY; RECURRENCE; SEROTONIN; SMOKING; SUICIDE, ATTEMPTED; THIOPHENES; TRYPTOPHAN; YOUNG ADULT;

EID: 79960266118     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2011.05.002     Document Type: Article

References (60)

1. Almeida-Montes L.G., Valles-Sanchez V., Moreno-Aguilar J., Chavez-Balderas R.A., Garcia-Marin J.A., Cortes Sotres J.F., Hheinze-Martin G. Relation of serum cholesterol, lipid, serotonin and tryptophan levels to severity of depression and to suicide attempts. J. Psychiatry Neurosci. 2000, 25:371-377.
2. Amori L., Wu H.Q., Marinozzi M., Pellicciari R., Guidetti P., Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 2009, 159:196-203.
3. Baron D.A., Hardie T., Baron S.H. Possible association of interleukin-2 treatment with depression and suicide. J. Am. Osteopath. Assoc. 1993, 93:799-800.
4. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
5. Chess A.C., Simoni M.K., Alling T.E., Bucci D.J. Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 2007, 33:797-804.
6. Chess A.C., Landers A.M., Bucci D.J. L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behav. Brain Res. 2009, 201:325-331.
7. Clark D.B. Serum tryptophan ratio and suicidal behavior in adolescents: a prospective study. Psychiatry Res. 2003, 119:199-204.
8. Comings D.E., Muhleman D., Dietz G., Sherman M., Forest G.L. Sequence of human tryptophan 2,3-dioxygenase (TDO2): presence of a glucocorticoid response-like element composed of a GTT repeat and an intronic CCCCT repeat. Genomics 1995, 29:390-396.
9. Dantzer R., O'Connor J., Freund G., Johnson R., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
10. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
11. Dieperink E., Ho S.B., Tetrick L., Thuras P., Dua K., Willenbring M.L. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen. Hosp. Psychiatry 2004, 26:237-240.
12. First M., Williams J., Spitzer R., Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders 1997, American Psychiatric Publishing Inc., Washington D.C.
13. Fragoso Y.D., Frota E.R., Lopes J.S., Noal J.S., Giacomo M.C., Gomes S., Goncalves M.V., da Gama P.D., Finkelsztejn A. Severe depression, suicide attempts, and ideation during the use of interferon beta by patients with multiple sclerosis. Clin. Neuropharmacol. 2010, 33:312-316.
14. Fu X., Zunich S.M., O'Connor J.C., Kavelaars A., Dantzer R., Kelley K.W. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J. Neuroinflam. 2010, 7:43.
15. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 1991, 56:2007-2017.
16. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
17. Hayaishi O. Properties and function of indoleamine 2,3-dioxygenase. J. Biochem. 1976, 79:13P-21P.
18. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 2001, 21:7463-7473.
19. Hughes J.R. Smoking and suicide: a brief overview. Drug Alcohol Depend. 2008, 98:169-178.
20. Janelidze S., Mattei D., Westrin A., Traskman-Bendz L., Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav. Immun. 2011, 25:335-339.
21. Janssen H.L., Brouwer J.T., van der Mast R.C., Schalm S.W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis. J. Hepatol. 1994, 21:241-243.
22. Keilp J.G., Sackeim H.A., Brodsky B.S., Oquendo M.A., Malone K.M., Mann J.J. Neuropsychological dysfunction in depressed suicide attempters. Am. J. Psychiatry 2001, 158:735-741.
23. Kim Y.K., Lee S.W., Kim S.H., Shim S.H., Han S.W., Choi S.H., Lee B.H. Differences in cytokines between non-suicidal patients and suicidal patients in major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:356-361.
24. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav. Brain Res. 2010, 210:84-91.
25. Laugeray A., Launay J.M., Callebert J., Surget A., Belzung C., Barone P.R. Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice. focus on individual differences. Pharmacol. Biochem. Behav. 2011, 98:161-168.
26. Lindqvist D., Janelidze S., Hagell P., Erhardt S., Samuelsson M., Minthon L., Hansson O., Björkqvist M., Träskman-Bendz L., Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiatry 2009, 66:287-292.
27. Linkswiler H. Biochemical and physiological changes in vitamin B6 deficiency. Am. J. Clin. Nutr. 1967, 20:547-561.
28. Maes M., Meltzer H.Y., Scharpe S., Bosmans E., Suy E., De Meester I., Calabrese J., Cosyns P. Relationships between lower plasma l-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res. 1993, 49:151-165.
29. Maes M., Yirmyia R., Noraberg J., Brene S., Hibbeln J., Perini G., Kubera M., Bob P., Lerer B., Maj M. The inflammatory and neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab. Brain Dis. 2009, 24:27-53.
30. Mann J. Neurobiology of suicidal behaviour. Nat. Rev. Neurosci. 2003, 4:819-828.
31. Mann J.J., Waternaux C., Haas G.L., Malone K.M. Toward a clinical model of suicidal behavior in psychiatric patients. Am. J. Psychiatry 1999, 156:181-189.
32. Mann J., Currier D., Stanley B., Oquendo M., Amsel L.V., Ellis S.P. Can biological tests assist prediction of suicide in mood disorders?. Int. J. Neuropsychopharmacol. 2006, 9:465-474.
33. Mann J.J., Arango V.A., Avenevoli S., Brent D.A., Champagne F.A., Clayton P., Currier D., Dougherty D.M., Haghighi F., Hodge S.E., Kleinman J., Lehner T., McMahon F., Moscicki E.K., Oquendo M.A., Pandey G.N., Pearson J., Stanley B., Terwilliger J., Wenzel A. Candidate endophenotypes for genetic studies of suicidal behavior. Biol. Psychiatry 2009, 65:556-563.
34. Marzuk P.M., Hartwell N., Leon A.C., Portera L. Executive functioning in depressed patients with suicidal ideation. Acta Psychiatr. Scand. 2005, 112:294-301.
35. Mayersbach P., Fuchs D., Schennach H. Performance of a fully automated quantitative neopterin measurement assay in a routine voluntary blood donation setting. Clin. Chem. Lab. Med. 2010, 48:373-377.
36. McGirr A., Diaconu G., Berlim M.T., Turecki G. Personal and family history of suicidal behaviour is associated with lower peripheral cortisol in depressed outpatients. J. Affect. Disord. 2010.
37. Miller C.L., Llenos I.C., Cwik M., Walkup J., Weis S. Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. Neurochem. Int. 2008, 52:1297-1303.
38. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol. Psychiatry 2007, 12:988-1000.
39. Murr C., Widner B., Wirleitner B., Fuchs D. Neopterin as a marker for immune system activation. Curr. Drug Metab. 2002, 3:175-187.
40. O'Connor J.C., Lawson M.A., Andre C., Briley E.M., Szegedi S.S., Lestage J., Castanon N., Herkenham M., Dantzer R., Kelley K.W. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J. Immunol. 2009, 182:3202-3212.
41. Oquendo M.A., Halberstam B., Mann J.J. Risk factors for suicidal behavior: utility and limitations of research instruments. Standardized Evaluation in Clinical Practice 2003, 103-130. APPI Press, Washington, D.C. M.B. First (Ed.).
42. Pfeffer C.R., McBride P.A., Anderson G.M., Kakuma T., Fensterheim L., Khait V. Peripheral serotonin measures in prepubertal psychiatric inpatients and normal children: associations with suicidal behavior and its risk factors. Biol. Psychiatry 1998, 44:568-577.
43. Pfefferkorn E.R., Rebhun S., Eckel M. Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. J. Interferon Res. 1986, 6:267-279.
44. Poeggeler B., Rassoulpour A., Wu H.Q., Guidetti P., Roberts R.C., Schwarcz R. Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-d-aspartate neurotoxicity. Neuroscience 2007, 148:188-197.
45. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
46. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
47. Ren S., Liu H., Licad E., Correia M.A. Expression of rat liver tryptophan 2,3-dioxygenase in Escherichia coli: structural and functional characterization of the purified enzyme. Arch. Biochem. Biophys. 1996, 333:96-102.
48. Roggenbach J., Muller-Oerlinghausen B., Franke L., Uebelhack R., Blank S., Ahrens B. Peripheral serotonergic markers in acutely suicidal patients. 1. Comparison of serotonergic platelet measures between suicidal individuals, nonsuicidal patients with major depression and healthy subjects. J. Neural Transm 2007, 114:479-487.
49. Schrocksnadel K., Wirleitner B., Winkler C., Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin. Chim. Acta 2006, 364:82-90.
50. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 2002, 303:1-10.
51. Shah, A. 2011. Suicide rates: age-associated trends and their correlates1. J. Inj. Violence Res. 4, in press.
52. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H.G., Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J. Psychiatr. Res. 2008, 42:151-157.
53. Tiihonen J., Virkkunen M., Rasanen P., Pennanen S., Sainio E.L., Callaway J., Halonen P., Liesivuori J. Free l-tryptophan plasma levels in antisocial violent offenders. Psychopharmacology (Berl.). 2001, 157:395-400.
54. Tonelli L.H., Stiller J., Rujescu D., Giegling I., Schneider B., Maurer K., Schnabel A., Möller H.J., Chen H.H., Postolache T.T. Elevated cytokine expression in the orbitofrontal cortex of victims of suicide. Acta Psychiatr. Scand. 2008, 117:198-206.
55. Uchida K., Usami M., Bandow H., Harada I. Characteristics of substrates and inhibitors in binding to rat liver l-tryptophan 2,3-dioxygenase: a Fourier transform infrared and kinetic study. Biochim. Biophys. Acta 1992, 1121:153-159.
56. Vignau J., Soichot M., Imbenotte M., Jacquemont M.C., Danel T., Vandamme M., Lhermitte M., Allorge D. Impact of tryptophan metabolism on the vulnerability to alcohol-related blackouts and violent impulsive behaviours. Alcohol Alcohol. 2010, 45:79-88.
57. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 2005, 10:538-544.
58. Widner B., Werner E.R., Schennach H., Wachter H., Fuchs D. Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin. Chem. 1997, 43:2424-2426.
59. Widner B., Laich A., Sperner-Unterweger B., Ledochowski M., Fuchs D. Neopterin production, tryptophan degradation, and mental depression-what is the link?. Brain Behav. Immun. 2002, 16:590-595.
60. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr. Bull. 2010, 36:211-218.